Quince Therapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 11, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 11, 2025
QNCX$31.73+8.1%Stored close · as of Oct 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
| For the three months ended June 30, 2025 and 2024 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Common Stock · AdditionalPaid in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders' | |||||||||
| Shares · Amount · Capital · Income / (Loss) · Deficit · Equity | |||||||||
| Balance as of March 31, 2025 | 44,089,142 | $44 | $408,082 | $1,957 | $(391,502) | $18,581 | |||
| Issuance of common stock and warrants in private placement offering, net | 6,671,928 | 6 | 740 | — | — | 746 | |||
| Issuance of common stock in connection with the ATM offerings, net | 2,766,549 | 3 | 2,887 | — | — | 2,890 | |||
| Issuance of common stock on exercise of stock options and vesting of restricted stock units | 96,561 | — | 96 | — | — | 96 | |||
| Stock based compensation | — | — | 1,273 | — | 1,273 | ||||
| Foreign currency translation adjustment | — | — | — | 4,216 | — | 4,216 | |||
| Unrealized loss on available for sale investments | — | — | — | (17) | — | (17) | |||
| Net loss | — | — | — | — | (16,049) | (16,049) | |||
| Balance as of June 30, 2025 | 53,624,180 | $53 | $413,078 | $6,156 | $(407,551) | $11,736 | |||
| Balance March 31, 2024 | 43,215,233 | $43 | $403,102 | $1,825 | $(330,793) | $74,177 | |||
| Issuance of common stock on exercise of stock options and vesting of restricted stock units | 61,373 | — | 35 | — | — | 35 | |||
| Restricted stock award retirement | — | — | — | ||||||
| Stock based compensation | — | — | 1,223 | — | — | 1,223 | |||
| Foreign currency translation adjustment | — | — | — | (726) | — | (726) | |||
| Unrealized loss on available for sale investments | — | — | — | (12) | — | (12) | |||
| Net loss | — | — | — | — | (27,729) | (27,729) | |||
| Balance June 30, 2024 | 43,276,606 | $43 | $404,360 | $1,087 | $(358,522) | $46,968 | |||
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
| For the six months ended June 30, 2025 and 2024 | ||||||
|---|---|---|---|---|---|---|
| Common Stock · Additional · AccumulatedOtherComprehensive · Accumulated · TotalStockholders' | ||||||
| Shares | Amount | Paid in | Income / (Loss) | Deficit | Equity | |
| Balance as of December 31, 2024 | 44,001,643 | $44 | $406,609 | $(35) | $(376,472) | $30,146 |
| Issuance of common stock and warrants in private placement offering, net | 6,671,928 | 6 | 740 | — | — | 746 |
| Issuance of common stock in connection with the ATM offerings, net | 2,766,549 | 3 | 2,887 | — | — | 2,890 |
| Issuance of common stock on exercise of stock options and vesting of restricted stock units | 184,060 | — | 183 | — | — | 183 |
| Stock based compensation | — | — | 2,659 | — | — | 2,659 |
| Foreign currency translation adjustment | — | — | — | 6,261 | — | 6,261 |
| Unrealized loss on available for sale investments | — | — | — | (70) | — | (70) |
| Net loss | — | — | — | — | (31,079) | (31,079) |
| Balance as of June 30, 2025 | 53,624,180 | $53 | $413,078 | $6,156 | $(407,551) | $11,736 |
| Balance as of December 31, 2023 | 42,973,215 | $43 | $401,638 | $3,047 | $(319,644) | $85,084 |
| Issuance of common stock on exercise of stock options | 303,391 | — | 225 | — | — | 225 |
| Stock based compensation | — | — | 2,497 | — | — | 2,497 |
| Foreign currency translation adjustment | — | — | — | (1,955) | — | (1,955) |
| Unrealized loss on available for sale investments | — | — | — | (5) | — | (5) |
| Net loss | — | — | — | — | (38,878) | (38,878) |
| Balance as of June 30, 2024 | 43,276,606 | $43 | $404,360 | $1,087 | $(358,522) | $46,968 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.